328 related articles for article (PubMed ID: 36883553)
21. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
[TBL] [Abstract][Full Text] [Related]
22. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
23. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
24. Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair.
Phillips DH
DNA Repair (Amst); 2018 Nov; 71():6-11. PubMed ID: 30236628
[TBL] [Abstract][Full Text] [Related]
25. DNA Repair Footprint Uncovers Contribution of DNA Repair Mechanism to Mutational Signatures.
Wojtowicz D; Leiserson MDM; Sharan R; Przytycka TM
Pac Symp Biocomput; 2020; 25():262-273. PubMed ID: 31797602
[TBL] [Abstract][Full Text] [Related]
26. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694
[TBL] [Abstract][Full Text] [Related]
27. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
28. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
[TBL] [Abstract][Full Text] [Related]
29. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
30. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
31. Inherited breast cancer: an emerging picture.
Welcsh PL; Schubert EL; King MC
Clin Genet; 1998 Dec; 54(6):447-58. PubMed ID: 9894790
[TBL] [Abstract][Full Text] [Related]
32. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
33. Copy number alteration features in pan-cancer homologous recombination deficiency prediction and biology.
Yao H; Li H; Wang J; Wu T; Ning W; Diao K; Wu C; Wang G; Tao Z; Zhao X; Chen J; Sun X; Liu XS
Commun Biol; 2023 May; 6(1):527. PubMed ID: 37193789
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
35. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
[TBL] [Abstract][Full Text] [Related]
36. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.
Zámborszky J; Szikriszt B; Gervai JZ; Pipek O; Póti Á; Krzystanek M; Ribli D; Szalai-Gindl JM; Csabai I; Szallasi Z; Swanton C; Richardson AL; Szüts D
Oncogene; 2017 Feb; 36(6):746-755. PubMed ID: 27452521
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer.
Ma J; Setton J; Lee NY; Riaz N; Powell SN
Nat Commun; 2018 Aug; 9(1):3292. PubMed ID: 30120226
[TBL] [Abstract][Full Text] [Related]
38. Experimental systems for the analysis of mutational signatures: no 'one-size-fits-all' solution.
Ivanov D; Hwang T; Sitko LK; Lee S; Gartner A
Biochem Soc Trans; 2023 Jun; 51(3):1307-1317. PubMed ID: 37283472
[TBL] [Abstract][Full Text] [Related]
39. Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Leong T; Whitty J; Keilar M; Mifsud S; Ramsay J; Birrell G; Venter D; Southey M; McKay M
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):959-65. PubMed ID: 11072151
[TBL] [Abstract][Full Text] [Related]
40. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
